Olfactory loss is well reported symptom of COVID-19. Given the need to find a standardized treatment to lessen the risk of developing long-term olfactory illness in COVID patients, this study found that the use of oral corticosteroids and olfactory training may be effective in these patients.

This study evaluated the effectiveness of corticosteroids taken orally and olfactory training as a therapy for persistent olfactory dysfunction (loss of smell) due to COVID-19.

This pilot study included non-hospitalized patients with unexpected loss of smell and positive COVID-19. Persistent dysosmia was identified in these patients via psychophysical testing. Thereafter, these patients were subjected to a course of oral corticosteroids plus olfactory training for 10 days (9 patients), or just olfactory training (18 patients). Following 10 weeks, all patients were subjected to another olfactory test.

Patients on corticosteroids taken orally plus olfactory training portrayed considerable improved olfactory score (threshold discrimination identification / TDI score) and negligible clinically important difference for subjective improvement of smell (p = 0.007). Minimum and temporary side effects were observed in 3 patients with oral corticosteroids.

Oral corticosteroids along with olfactory training when used for short duration are effective and safe in patients with ongoing dysosmia recovery from olfactory loss as a result of COVID-19. Future examination to validate these conclusions is required.